What Onkure Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 8 |
| Total trades | 2 | 10 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 10 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer | Sep 21 | Open-market sale · S | −302 | $2.97 | −$898 | 18,500 |
| Saccomano Nicholas A | President and CEO | Sep 21 | Open-market sale · S | −87 | $2.97 | −$259 | 11,160 |
| Leverone Jason A. | Chief Financial Officer | Jun 22 | Open-market sale · S | −303 | $4.40 | −$1.33K | 18,802 |
| Saccomano Nicholas A | President and CEO | Jun 22 | Open-market sale · S | −86 | $4.40 | −$378 | 11,247 |
| Leverone Jason A. | Chief Financial Officer | Mar 23 | Open-market sale · S | −301 | $4.16 | −$1.25K | 16,000 |
| Saccomano Nicholas A | President and CEO | Mar 23 | Open-market sale · S | −86 | $4.16 | −$357 | 7,333 |
| Manke Isaac | Director | Dec 31 | Grant / award · A | +5,258 | — | — | 20,583 |
| Mathers Edward T | Director | Dec 31 | Grant / award · A | +3,911 | — | — | 15,310 |
| Leverone Jason A. | Chief Financial Officer | Dec 22 | Open-market sale · S | −302 | $2.97 | −$896 | 16,301 |
| Saccomano Nicholas A | President and CEO | Dec 22 | Open-market sale · S | −87 | $2.97 | −$258 | 7,419 |
| Manke Isaac | Director | Sep 30 | Grant / award · A | +5,545 | — | — | 15,325 |
| Mathers Edward T | Director | Sep 30 | Grant / award · A | +4,125 | — | — | 11,399 |
| Leverone Jason A. | Chief Financial Officer | Sep 22 | Open-market sale · S | −303 | $2.62 | −$795 | 12,603 |
| Saccomano Nicholas A | President and CEO | Sep 22 | Open-market sale · S | −88 | $2.62 | −$231 | 3,506 |
| Manke Isaac | Director | Jun 30 | Grant / award · A | +6,311 | — | — | 9,780 |
| Mathers Edward T | Director | Jun 30 | Grant / award · A | +4,694 | — | — | 7,274 |
| Leverone Jason A. | Chief Financial Officer | Jun 23 | Open-market sale · S | −303 | $2.38 | −$722 | 12,906 |
| Saccomano Nicholas A | President and CEO | Jun 23 | Open-market sale · S | −88 | $2.38 | −$210 | 3,594 |
| Cormorant Asset Management, Lp | Insider | May 15 | Open-market sale · S | −1,813,439 | $1.85 | −$3.36M | 0 |
| Acorn BIOVENTURES, L.p. | 10% owner | May 15 | Open-market buy · P | +1,129,730 | $1.85 | +$2.09M | 1,129,730 |
Loading...
